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LETTER TO THE EDITOR
Response to the letter from Drs van Oortmarssen and Habbema
Sir - Our primary purpose was to develop a consistent model
based on Swedish statistics to describe the natural history of
cervical neoplasia from the time when the patient develops
cancer in situ (CIS) up to the time of death (Gustafsson &
Adanmi, 1989). Conditions in Sweden and the need for a
dynamic model favoured a mathematical approach rather
than a statistical one. This meant that the concepts, assump-
tions, definitions, etc., had to be somewhat different from
those usually used in a statistical context.
For many years Sweden has had a national cancer register
which includes all cases of cancer in situ. However, 75-80%
of the smears are taken outside the organised screening pro-
gramme, and these examinations are not registered but all
findings of cancer in situ and invasive cancer must be
reported. Thus, while this situation is ideal for relating the
number of in situ cases found and eliminated to the decrease
in invasive cancer and mortality, it is difficult to assess
matters such as cost-effectiveness, test sensitivity, participa-
tion patterns, etc.
Concerning the main issues raised in the letter from van
Oortmarssen and Habbema: 1. These authors claim that our
estimate of the proportion (P) of new in situ cases that would
progress into invasive cancer without screening (12.2%) is
too low. 2. They estimate the detection rates of cancer in situ
from our results and calculate that these would correspond
to a detection rate of between 25 and 30 per 1,000 women on
a first screening of women aged 30 to 45 years. 3. They claim
that our figures imply that 85% of the cases of cancer in situ
detected by screening are treated unnecessarily. (In our paper
(Gustafsson & Adami, 1989) we stated that 80% is 'typical'
although we said the figure ranged between 77% and 85%
since it varies with age.)
In model terms these statements all question whether the
rates of cancer in situ in Sweden are correct. The incidence
rates of invasive cancer and the mortality rates in countries
like Holland, the UK and Canada are rather similar to those
in Sweden for the period studied (Canadian Task Force on
Screening, 1976). But the in situ figures are several times
higher in Sweden than estimates from corresponding coun-
tries. In Sweden about 4,000 cases of cancer in situ are
reported annually; this figure should be compared to the
reported number of cases of invasive cancer, which has
decreased from about 800 before screening to about 500 per
year in 1985 (National Board of Health and Welfare, 1960-
1984). A dynamic model and birth cohort figures are needed
for accurate calculations, but it seems obvious that the vast
majority of cases of cancer in situ would not have progressed
to invasive cancer if they had not been detected.
Although nobody has yet succeeded in explaining the dis-
crepancy between the rates ofcancer in situ in Sweden and in
other countries, we belive that there are some factors which
may be involved. One factor may be the current method of
classifying cancer in situ. In Sweden severe dysplasia on the
borderline to cancer in situ must by law be reported and such
cases are classified as cancer in situ in the Swedish Cancer
Registry (National Board of Health and Welfare, 1960-
1984). Another contributory factor might be that, with the
large amount of screening in Sweden, a greater number of
findings are made before regression occurs. However, it
seems that none ofthese explanations can entirely explain the
difference.
Van Oortmarssen and Habbema also argue that a wrong
estimate of parameter P will affect the estimate of the mean
duration of cancer in situ and the conclusions concerning the
absence of age-dependency. But what would lower rates of
cancer in situ mean to the model? The function of new in situ
cases according to age - Figure 7 in our report (Gustafsson
& Adami, 1989) - would have smaller values (but the same
shape), the proportional parameter P would be larger, and
the prevalence rates would be smaller. The rest of the results,
e.g. the mean duration of CIS, would be the same, as also
would the course of the effect of age, since the incidence of
invasive cancer and the mortality rates are not affected. The
absence of age dependency would still be valid.
Van Oortmarssen and Habbema also suggest a comparison
with empirical data obtained from prevalence screening and
repeated screening in Sweden. However, a comparison is
difficult to make because of the lack of registrations, ques-
tions concerning sensitivity and the fact that Pap smears are
often used to estimate the number of cancer in situ. For the
same reasons, accurate estimates cannot be made from
repeated screening. The best information available is pro-
vided by the gynaecological mass examinations in 1967-68
(National Board of Health and Welfare, 1970), in which the
results agreed will with those from our model. Thus, at ages
30-45 years, detection rates of cancer in situ of 19 per 1,000
for 1967 (of the 7,411 women examined) and 28 per 1,000 for
1968 (of the 40,800 women examined) were found, compared
to a prevalence of 32 per 1,000 in our model estimates.
Other data referred to by van Oortmarssen and Habbema
(Bjerre, 1969; Kjellgren, 1977) concern small regions in the
country where there is a 13.5 times difference between the
southern and the northern parts of Sweden. Since the age-
standardised rates of invasive cancer differ only two-fold
between these areas, it is unlikely that both ofthese estimates
of prevalence are correct. In fact, there is clear evidence that
the study of Bjerre (1969), but not that of Kjellgren (1977),
represents prevalence screening.
It is unlikely that a high prevalence of hysterectomy has
substantially biased our estimates of the natural history of
cervical neoplasia. As previously reported by Pettersson et al.
(1985): 'Hysterectomy played a minor role in Sweden and
was never a standard method for treatment of in situ car-
cinoma. Thus the number of uteri at risk is not significantly
different from the number of women at risk.' We have
recently estimated the prevalence of hysterectomy to be
about 7% in a population sample ofwomen aged 60 years or
more (Naessen et al., 1990). Since there is no exact infor-
mation available about the prevalence of hysterectomy in
different age groups, we chose to use the number of women
instead of the women at risk. Our definitions strictly follow
this choice.
Yours etc.,
L. Gustafsson,
Department of Technology,
Box 534, S-751 85 Uppsala,
Sweden
H.-O. Adami,
Department of Surgery,
University Hospital,
S-751 85 Uppsala,
Sweden
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